Literature DB >> 27294076

Can Alarming Improve Compliance with Weekly Bisphosphonate in Patients with Osteoporosis?

Jae-Hwi Nho1, Young-Kyun Lee2, Yong-Chan Ha3, Chung-Hyun Kim1, You-Sung Suh1, Kyung-Hoi Koo2.   

Abstract

BACKGROUND: Although bisphosphonate is effective for the prevention and treatment of osteoporosis, poor medication compliance is a key-limiting factor. We determined whether alarm clock could improve compliance with weekly bisphosphonate in patients with osteoporosis, by comparing with age- and gender-matched control group.
METHODS: Fifty patients with osteoporosis were recruited and participated in alarm clock group. Patients were asked to take orally weekly risedronate for 1 year, and received alarm clock to inform the time of taking oral bisphosphonate weekly. Using the propensity score matching with age and gender, 50 patients were identified from patients with osteoporosis medication. We compared the compliance with bisphosphonate using medication possession ratio (MPR) between two groups.
RESULTS: Although there was no significant difference of baseline characteristics between both groups, the mean MPR (0.80±0.33) of alarm clock group was higher than that (0.56±0.34) of control group (P<0.001).
CONCLUSIONS: Alarming could improve the compliance with weekly oral bisphosphonate in patients with osteoporosis.

Entities:  

Keywords:  Bisphosphonate osteoporosis; Patient compliance

Year:  2016        PMID: 27294076      PMCID: PMC4900960          DOI: 10.11005/jbm.2016.23.2.51

Source DB:  PubMed          Journal:  J Bone Metab        ISSN: 2287-6375


INTRODUCTION

Osteoporosis is a systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture.[1234] Bisphosphonate is the most widely used drugs to prevent and treat osteoporosis.[56789] Although bisphosphonate is effective for the treatment of osteoporosis and prevention of osteoporotic fractures, poor medication compliance is a key-limiting factor in terms of the prevention and treatment of osteoporosis.[5671011] Bisphosphonate-related factors including gastroesophaseal irritation and complex method of ingestion have been well-known risk factors for low compliance with bisphosphonate.[121314] To overcome poor compliance, new type of bisphosphonate with various dose intervals have introduced. Bisphosphonates with longer interval have shown better compliance.[151617] However, there have been few intervention studies on improving compliance with bisphosphonate. Our purpose was to determine whether alarm clock could improve compliance with weekly bisphosphonate in patients with osteoporosis, by comparing with age- and gender-matched control group without alarm clock.

METHODS

This is a case-control study conducted with prospectively complied data. From May 2012 to May 2013, 50 patients with osteoporosis were recruited and participated in alarm clock group. The inclusion criteria were (1) 65 years of age and over, (2) diagnosis of osteoporosis (T-score below -2.5 standard deviation) based on the most recent bone mineral density (BMD) measurements (hip or spine, dual energy X-ray absorptiometry [DXA]), (3) without contraindications to oral bisphosphonate, (4) no cognitive impairment, and (4) ability of interview independently. All eligibility patients were asked to take orally weekly risedronate for 1 year, and received alarm clock to inform the time of taking oral bisphosphonate weekly (Fig. 1). Clocks were provided by Sanofi Aventis. In order to avoid selection bias, written informed consent was not required.
Fig. 1

Alarm clock will ring, when it reaches target day.

To obtain control group, the propensity score matching with age and gender was used. As control group, 50 patients, who had taken weekly oral risedronate for treatment of osteoporosis and were followed up for 12 months or more, were identified from patients with osteoporosis medication between 2005 and 2010. The medical records whom they had not received alarm clock in were reviewed to evaluate compliance with bisphosphonate. To compare the compliance between two groups, we analyzed compliance with bisphosphonates during 12 months after first prescription. Compliance with bisphosphonates was measured a period of 1 year of treatment after first prescription by using medication possession ratio (MPR) as the parameter.[918] MPR was defined as the sum of days of supply of osteoporosis medications divided by the length of follow-up, i.e., 365 days. Compliance was categorized with MPR<80% and MPR≥80%.[1819] The study protocol was reviewed and approved by the Institutional Review Boards and Ethics Committee.

1. Statistical analysis

For statistical analysis, student's t-test was used for continuous data and Pearson's chi-squared test for categorical data. All continuous data are expressed as means and standard deviations (SD). P-values<0.05 were considered significant.

RESULTS

There was no significant difference of baseline characteristics including age and gender between both groups (Table 1).
Table 1

Baseline characteristics of both groups

BMI, body mass index.

The mean MPR (0.80±0.33) of alarm clock group was higher than that (0.56±0.34) of control group (P<0.001).

DISCUSSION

To our knowledge, this is the first study that evaluates compliance with weekly oral bisphosphonate in patients alarmed with clock. This study presented that alarming could improve the compliance with weekly bisphosphonate in patients with osteoporosis. Poor compliance is a major challenge in contemporary therapeutics, because osteoporosis has asymptomatic feature itself like other silent chronic diseases. Higher ages, low socioeconomic status, low awareness on osteoporosis, various interval of administration, and adverse effect of bisphosphonate have been presented to be risk factors for low compliance with bisphosphonate.[121314] Identifying patients with high risk of low compliance and efforts to increase compliance are very important in treatment of osteoporosis. Complex dosing schedules related to other chronic diseases, such as hypertension, hyperlipidemia, and diabetes mellitus could lead to lack of compliance for osteoporosis medication. Simply forgetting to take the medication may also result in non-persistence or non-compliance in old ages.[2021] In a previous study, 24% of the patients answered that they occasionally forgot to refill a prescription, as the reason why they did not fill prescriptions with drug regimens.[21] Therefore, it is important to alarm patients taking the medication, not to forget. In this study, the MPR (0.56) of oral bisphosphonate without alarm clock is similar with that of another study.[2223] However, weekly bisphosphonate with alarm clock could improve MPR (0.80) obviously in this study. In this study, we used clock with alarming function. Currently, this intervention using alarming can be conducted with smartphone or message service using IT technology. There are some limitations. First, we did not perform randomized study, but used historical control group. But, not to intervene control group will be ethical problem. Second, we included only patients with weekly oral bisphosphonate. Third, we did not evaluate the change of BMD and compare the incidence of osteoporotic fracture. Fourth, we did not calculate a sample size prior to study. But, power of this study was 94.5% with type 1 error of 5%. This study, which is the first study to intervene for compliance with bisphosphonate, presented that alarming could improve the compliance with weekly bisphosphonate in patients with osteoporosis.
  23 in total

1.  Persistence and compliance of medications used in the treatment of osteoporosis--analysis using a large scale, representative, longitudinal German database.

Authors:  Volker Ziller; Karel Kostev; Ioannis Kyvernitakis; Jelena Boeckhoff; Peyman Hadji
Journal:  Int J Clin Pharmacol Ther       Date:  2012-05       Impact factor: 1.366

2.  Compliance with osteoporosis drug therapy and risk of fracture.

Authors:  D Weycker; D Macarios; J Edelsberg; G Oster
Journal:  Osteoporos Int       Date:  2006-10-05       Impact factor: 4.507

3.  The incidence and residual lifetime risk of osteoporosis-related fractures in Korea.

Authors:  Chanmi Park; Yong-Chan Ha; Sunmee Jang; Suhyun Jang; Hyun-Koo Yoon; Young-Kyun Lee
Journal:  J Bone Miner Metab       Date:  2011-06-07       Impact factor: 2.626

4.  Adherence and persistence in patients with postmenopausal osteoporosis treated with raloxifene.

Authors:  V Ziller; K Wetzel; I Kyvernitakis; B Seker-Pektas; P Hadji
Journal:  Climacteric       Date:  2010-10-21       Impact factor: 3.005

5.  Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.

Authors:  Ethel S Siris; Steven T Harris; Clifford J Rosen; Charles E Barr; James N Arvesen; Thomas A Abbott; Stuart Silverman
Journal:  Mayo Clin Proc       Date:  2006-08       Impact factor: 7.616

6.  A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.

Authors:  Deborah T Gold; Bradley C Martin; Jennifer R Frytak; Mayur M Amonkar; Felicia Cosman
Journal:  Curr Med Res Opin       Date:  2007-03       Impact factor: 2.580

7.  GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.

Authors:  P Hadji; V Claus; V Ziller; M Intorcia; K Kostev; T Steinle
Journal:  Osteoporos Int       Date:  2011-02-10       Impact factor: 4.507

Review 8.  Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.

Authors:  John P Bilezikian
Journal:  Am J Med       Date:  2009-02       Impact factor: 4.965

Review 9.  Colles fracture, spine fracture, and subsequent risk of hip fracture in men and women. A meta-analysis.

Authors:  Patrick Haentjens; Philippe Autier; John Collins; Brigitte Velkeniers; Dirk Vanderschueren; Steven Boonen
Journal:  J Bone Joint Surg Am       Date:  2003-10       Impact factor: 5.284

10.  Incidence and mortality following hip fracture in Korea.

Authors:  Hyun-Koo Yoon; Chanmi Park; Sunmee Jang; Suhyun Jang; Young-Kyun Lee; Yong-Chan Ha
Journal:  J Korean Med Sci       Date:  2011-07-27       Impact factor: 2.153

View more
  4 in total

Review 1.  Improving drug adherence in osteoporosis: an update on more recent studies.

Authors:  Ayesha Jaleel; Kenneth G Saag; Maria I Danila
Journal:  Ther Adv Musculoskelet Dis       Date:  2018-07-10       Impact factor: 5.346

Review 2.  Supporting patients to get the best from their osteoporosis treatment: a rapid realist review of what works, for whom, and in what circumstance.

Authors:  Z Paskins; O Babatunde; A Sturrock; L S Toh; R Horne; I Maidment
Journal:  Osteoporos Int       Date:  2022-06-11       Impact factor: 5.071

3.  Impact on Bisphosphonate Persistence and Compliance: Daily Postprandial Administration.

Authors:  Chan Ho Park; Ki Jin Jung; Jae-Hwi Nho; Ja-Hyung Kim; Sung Hun Won; Dong-Il Chun; Dong-Won Byun
Journal:  J Bone Metab       Date:  2019-02-28

4.  Alarm Services as a Useful Tool for Diagnosis and Management of Osteoporosis in Patients with Hip Fractures: A Prospective Observational Multicenter Study.

Authors:  Hyun-Soo Ok; Woo-Sung Kim; Yong-Chan Ha; Jae-Young Lim; Chan-Woo Jung; Young-Kyun Lee; Kyung-Hoi Koo
Journal:  J Bone Metab       Date:  2020-02-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.